Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 6/20 | 0.57 |
| ▸ | ACE | P12821 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29511108 | 1.00 | GHSR (0.57) | GHSRACEKDM4EMEN1LMNA | |
| SCHEMBL29511082 | 1.00 | GHSR (0.57) | GHSRACEKDM4EMEN1LMNA | |
| SCHEMBL3048070 | 0.94 | KDM4E (0.61) | GHSRACEKDM4EMEN1LMNA | |
| SCHEMBL29721506 | 0.94 | KDM4E (0.61) | GHSRACEKDM4EMEN1LMNA | |
| SCHEMBL1711405 | 0.94 | KDM4E (0.61) | GHSRACEKDM4EMEN1LMNA | |
| SCHEMBL1387764 | 0.94 | KDM4E (0.61) | GHSRACEKDM4EMEN1LMNA | |
| SCHEMBL29404993 | 0.94 | KDM4E (0.61) | GHSRACEKDM4EMEN1LMNA | |
| SCHEMBL29382469 | 0.94 | KDM4E (0.61) | GHSRACEKDM4EMEN1LMNA | |
| SCHEMBL14906252 | 0.94 | KDM4E (0.61) | GHSRACEKDM4EMEN1LMNA | |
| SCHEMBL27542236 | 0.94 | KDM4E (0.61) | GHSRACEKDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137591-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING ZINC SOLUBILIZATION AND ZINC UPTAKE IN PLANTS | Tenfold Technologies, LLC (US) | 2025-06-26 | — | — | WO | claimed |
| CN-117924413-A | Maotai-flavor round base wine polypeptide and application thereof in influencing flavor of wine body | 邵阳学院 | 2024-04-26 | — | — | CN | claimed |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| WO-2025137591-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING ZINC SOLUBILIZATION AND ZINC UPTAKE IN PLANTS | Tenfold Technologies, LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-117924413-A | Maotai-flavor round base wine polypeptide and application thereof in influencing flavor of wine body | 邵阳学院 | 2024-04-26 | — | — | CN | disclosed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | GHSR 190/4885ACE 3407/4885KDM4E 4029/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | GHSR 33/4885ACE 1785/4885KDM4E 4248/4885 |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | MC3R, MC1R, MC5R | GHSR 106/4885ACE 3249/4885KDM4E 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.